Clémence Henon

2.3k total citations
22 papers, 148 citations indexed

About

Clémence Henon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Clémence Henon has authored 22 papers receiving a total of 148 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 4 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Clémence Henon's work include Sarcoma Diagnosis and Treatment (10 papers), Brain Metastases and Treatment (4 papers) and Cardiac tumors and thrombi (4 papers). Clémence Henon is often cited by papers focused on Sarcoma Diagnosis and Treatment (10 papers), Brain Metastases and Treatment (4 papers) and Cardiac tumors and thrombi (4 papers). Clémence Henon collaborates with scholars based in France, Spain and Netherlands. Clémence Henon's co-authors include Lizza Hendriks, C. Le Péchoux, Sophie Cousin, Laura Mezquita, Julien Mazières, Jean Mourlanette, Roberto Ferrara, Clarisse Audigier-Valette, Gerben Bootsma and Angela Botticella and has published in prestigious journals such as Journal of Clinical Oncology, Science Advances and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Clémence Henon

20 papers receiving 145 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Clémence Henon France 7 88 83 16 13 13 22 148
Guzel Mukhametshina Russia 7 143 1.6× 91 1.1× 11 0.7× 26 2.0× 3 0.2× 15 190
G. Koumakis Greece 7 94 1.1× 27 0.3× 8 0.5× 15 1.2× 11 0.8× 21 149
Luca Dezzani Italy 7 52 0.6× 76 0.9× 12 0.8× 51 3.9× 17 1.3× 18 112
Elisabetta Gambale Italy 8 178 2.0× 116 1.4× 4 0.3× 47 3.6× 26 2.0× 19 246
Hamzeh Albaba Canada 6 113 1.3× 67 0.8× 6 0.4× 17 1.3× 4 0.3× 11 152
Regina Gironés Sarrió Spain 6 81 0.9× 73 0.9× 7 0.4× 20 1.5× 12 0.9× 28 161
Cristiane Gomes-Lima United States 10 66 0.8× 51 0.6× 5 0.3× 44 3.4× 5 0.4× 16 244
Jamal Misleh United States 7 93 1.1× 63 0.8× 10 0.6× 48 3.7× 37 2.8× 24 204
Chih-Hsun Yang Taiwan 5 42 0.5× 27 0.3× 3 0.2× 25 1.9× 11 0.8× 7 169
Montse Puigdemont Spain 7 47 0.5× 28 0.3× 7 0.4× 17 1.3× 39 3.0× 17 112

Countries citing papers authored by Clémence Henon

Since Specialization
Citations

This map shows the geographic impact of Clémence Henon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clémence Henon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clémence Henon more than expected).

Fields of papers citing papers by Clémence Henon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clémence Henon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clémence Henon. The network helps show where Clémence Henon may publish in the future.

Co-authorship network of co-authors of Clémence Henon

This figure shows the co-authorship network connecting the top 25 collaborators of Clémence Henon. A scholar is included among the top collaborators of Clémence Henon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clémence Henon. Clémence Henon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Assi, Tarek, Carine Ngo, Matthieu Faron, et al.. (2025). Therapeutic advances in Tenosynovial giant cell Tumor: Targeting the CSF1/CSF1R axis. Cancer Treatment Reviews. 134. 102904–102904. 1 indexed citations
3.
4.
5.
Baldini, Capucine, Yohann Loriot, Clémence Henon, et al.. (2024). Is Local Ablative Stereotactic Radiation Therapy a Valuable Rescue Strategy for Time on Drug in Patients Enrolled in Phase I Trials?. International Journal of Radiation Oncology*Biology*Physics. 120(5). 1245–1256. 1 indexed citations
6.
Blay, Jean‐Yves, Nelly Firmin, Olivier Collard, et al.. (2024). 52O Resistance to imatinib induced by treatment interruption in advanced GIST: Long-term outcome of the randomized BFR14 study. ESMO Open. 9. 102442–102442. 1 indexed citations
7.
Cesne, Axel Le, Sylvie Chabaud, Nicolas Penel, et al.. (2024). 55O IMADGIST: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse. ESMO Open. 9. 102445–102445. 1 indexed citations
8.
Smolenschi, Cristina, Antoine Hollebecque, Damien Vasseur, et al.. (2023). 1659P The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials. Annals of Oncology. 34. S913–S914. 1 indexed citations
9.
Assi, Tarek, Carine Ngo, Matthieu Faron, et al.. (2023). Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review. Current Treatment Options in Oncology. 24(11). 1598–1613. 1 indexed citations
10.
Dufresne, Armelle, Daniel Pissaloux, Carine Ngo, et al.. (2023). Natural history and treatment efficacy in an ambispective case series of NTRK-rearranged mesenchymal tumors. ESMO Open. 8(2). 101202–101202. 10 indexed citations
11.
Baschieri, Francesco, Jorge Barbazán, Clémence Henon, et al.. (2023). Fibroblasts generate topographical cues that steer cancer cell migration. Science Advances. 9(33). eade2120–eade2120. 22 indexed citations
12.
Ibrahim, Rebecca, Tarek Assi, Rita Khoury, et al.. (2023). Desmoid-type fibromatosis: Current therapeutic strategies and future perspectives. Cancer Treatment Reviews. 123. 102675–102675. 4 indexed citations
13.
Watson, Sarah, Benjamin Verret, Stanislas Ropert, et al.. (2022). Single‐agent gemcitabine in patients with advanced, pre‐treated angiosarcoma: A multicenter, retrospective study. Cancer Medicine. 12(3). 3160–3166. 10 indexed citations
14.
Hindi, Nadia, Evan Rosenbaum, Rainer Hamacher, et al.. (2021). Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: Updated results from sixty patients.. Journal of Clinical Oncology. 39(15_suppl). 11564–11564. 4 indexed citations
15.
Henon, Clémence, Jordi Remón, & Lizza Hendriks. (2020). Combination Treatments with Immunotherapy in Brain Metastases Patients. Future Oncology. 16(23). 1691–1705. 4 indexed citations
16.
Hendriks, Lizza, Gerben Bootsma, Jean Mourlanette, et al.. (2019). Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors. European Journal of Cancer. 116. 182–189. 45 indexed citations
17.
Hendriks, Lizza, Clémence Henon, Laura Mezquita, et al.. (2018). Impact of central nervous system (CNS) involvement in advanced non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology. 36(15_suppl). 9066–9066. 1 indexed citations
18.
Henon, Clémence, et al.. (2017). Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer. Clinical Genitourinary Cancer. 15(3). e493–e495. 1 indexed citations
19.
Henon, Clémence, Delphine Lissa, Xavier Paolettí, et al.. (2017). Patient-reported tolerability of adverse events in phase 1 trials. ESMO Open. 2(2). e000148–e000148. 19 indexed citations
20.
Henon, Clémence, Laura Mezquita, Édouard Auclin, et al.. (2017). P2.07-005 Impact of Baseline Leptomeningeal and Brain Metastases on Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology. 12(11). S2417–S2417. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Guzel Mukhametshina Breakdown of academic impact, for papers by G. Koumakis Breakdown of academic impact, for papers by Luca Dezzani Breakdown of academic impact, for papers by Elisabetta Gambale Breakdown of academic impact, for papers by Hamzeh Albaba Breakdown of academic impact, for papers by Regina Gironés Sarrió Breakdown of academic impact, for papers by Cristiane Gomes-Lima Breakdown of academic impact, for papers by Jamal Misleh Breakdown of academic impact, for papers by Chih-Hsun Yang Breakdown of academic impact, for papers by Montse Puigdemont
Rankless by CCL
2026